// App-Quantinova.ai

: Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Researchers

Presenter

  • Augusto B Federici

Principal Investigators

  • Mohammad-Reza Baghaipour

  • Giancarlo Castaman

  • Peyman Eshghi

  • Jenny Goudemand

  • Charles RM Hay

  • Hamid Hoorfar

  • Mehran Karimi

  • Bijan Keikhaei

  • Riitta Lassila

  • Frank Leebeek

  • Maria Fernanda Lopez Fernandez

  • Renato Marino

  • Ian Peake

  • Rafael Parra Lpez

  • Flora Peyvandi

  • Cristina Santoro

  • Simona Maria Siboni

  • Alberto Tosetto

  • Marc Trossaert

  • Jeroen C.J. Eikenboom

Medical Centers

  • Hematology and Transfusion Medicine, Hematology and Transfusion Medicine, University of Milan, Milano, Italy

  • Hemophilia‐Thalassaemia Center of Mashhad Sarvar Clinic, Mashhad University of Medical Science,, Mashhad, Iran, Islamic Republic of

  • Hemophilia‐Thalassaemia Center of Mashhad Sarvar Clinic, Mashhad University of Medical Science,, Mashhad, Iran, Islamic Republic of

  • Iranian Hemophilia Comprehensive Treatment Centre, Iranian Hemophilia Society, Tehran, Iran, Islamic Republic of

  • Hemophilia and Thrombosis Center, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

  • Mofid Comprehensive Care Centre for Children with Hemophilia, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of

  • Haematology Department, University of Lille, Lille, France

  • Manchester Royal Infirmary, Manchester University, Department of Hematology, Manchester, United Kingdom

  • Hemophilia Center, Esfahan University of Medical Science, Esfahan, Iran, Islamic Republic of

  • Hematology Research Center,, Shiraz University of Medical Sciences, Shiraz, Iran

  • Research Center for Thalassemia & Hemoglobinopathy, Division of Hematology & Oncology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of

  • Helsinki University Central Hospital, Helsinki, FIN

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Complejo Hospitalario Universitario de A Coruña, Servicio de Hematología y Hemoterapia, A Coruña, Spain

  • Hemostasis and Thrombosis Center, Azienda Ospedaliera Policlinico Consorziale, Bari, Italy

  • Department of Infection, Immunity and Cardiovascular Disease, Univeristy of Sheffield

  • Unidad de Hemofilia, Hospital Universitario Valld'Hebron, Barcelona, Spain

  • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Hemophilia & Thrombosis Centre, Milano, Italy

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milan, Italy

  • Hematology Department, San Bortolo Hospital,Vicenza, Italy

  • Centre Régional de Traitement de l'Hémophilie, Laboratoire d'Hématologie, Nantes, France

  • Department of Thrombosis and Hemostasis, Leiden Univ. Medical Center, Leiden, NLD

Locations

  • Iran

  • Italy

  • France

  • United Kingdom

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • rFVIIa

  • rFVIII

  • Wilfactin

  • Haemate-P

  • Alphanate

  • Wilate

  • FVIII

Outcome

  • N/A

Study Design

  • Observational

  • Non Interventional

  • Multinational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT02460458

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved